AbbVie Inc. (NYSE:ABBV)

CAPS Rating: 5 out of 5

Recs

0
Player Avatar XMFChaodan (78.62) Submitted: 1/30/2013 3:12:37 PM : Outperform Start Price: $36.58 ABBV Score: +6.66

Spinoff of Abbot Laboratories. This will most likely unlock value by allowing the company to be able to focus more on the experimental aspect of it. It also carries a portfolio of the drugs that they had invented themselves, or "unestablished." It holds the Humira patent which is due to expire in 2016. But until then, Humira is doing exceptionally well and is a leading brand for arthritis and Crohn's Disease. The drug manufacturing process is long and arduous, therefore we are unsure of the prospects of AbbVie developing another drug that is just as successful as Humira after the patent expiration. Meanwhile, the marketplace is also extremely competitive, with numerous pharmaceuticals vying for market share for their own drugs.

Featured Broker Partners


Advertisement